Researchers Tested New Male Contraceptive Methods
Clinical trials for hormone-free pills and injectable hydrogels are underway in the United States.
Updated on Oct. 12, 2026 in Men’s Health
Live Poll
Should federal resources be prioritized to accelerate the development of male birth control options?
Scientists in the United States have progressed in testing new male contraceptive options, including hormone-free daily pills and sperm-blocking procedures. Recent trials evaluate the efficacy and safety of these varied approaches to fertility management.
Why it matters
Expanding the variety of male contraceptive methods aims to provide more options for reproductive health and family planning. Researchers are working to prove the effectiveness and safety of these methods to ensure they meet clinical standards.
Clinical trials for the NES/T hormonal gel reported that 86 percent of 222 participants reached sperm suppression targets by week 15. Other studies include initial safety testing on 16 men for YCT-529 and a 10-man trial for the hormone-free PausePill.
The players
NEXT Life Sciences
This company is the developer behind the hormone-free PausePill, which is currently undergoing clinical trials.
YourChoice Therapeutics
This organization is responsible for the development of YCT-529, a daily hormone-free contraceptive pill for men.
The details
The hormone-free PausePill, also known as NLS-133, is designed to temporarily prevent sperm from entering ejaculation for 24 hours. Meanwhile, the Plan A procedure focuses on injecting a reversible hydrogel into tubes that carry sperm to act as a physical barrier.
Timeline
At week 15, 86 percent of NES/T trial participants reached sperm suppression targets.
Health Landscape
The rise in clinical research for male contraception aligns with the 39% to 49% shift in U.S. interest post-Roe v. Wade. These developments mark a transition from traditional methods to a broader array of experimental pharmacological and mechanical interventions.
These clinical developments remain in the research phase and are not yet available for public use. Future access to these contraceptives will depend on successful trial results and subsequent regulatory evaluations for safety and efficacy.
The takeaway
The development of diverse contraceptive options seeks to provide men with more agency in reproductive health. While research is ongoing, these trials represent an effort to bridge the gap in available fertility control methods.
Further reading
Learn more about advancements in reproductive care in the Men’s Health section.
Source note: This article includes information reported by VICE.
Live Poll
Should federal resources be prioritized to accelerate the development of male birth control options?
